Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Description

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation

Conditions

Advanced NSCLC, Metastatic Lung Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation

A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Condition
Advanced NSCLC
Intervention / Treatment

-

Contacts and Locations

Anchorage

Local Institution - Unk025, Anchorage, Alaska, United States, 99508

Glendale

Local Institution - 017-591, Glendale, Arizona, United States, 85304

Phoenix

Local Institution - 017-821, Phoenix, Arizona, United States, 85004

Anaheim

Local Institution - Unk047, Anaheim, California, United States, 92805

Fountain Valley

Local Institution - 017-936C, Fountain Valley, California, United States, 92708

Fountain Valley

MemorialCare - Orange Coast Medical Center, Fountain Valley, California, United States, 92708

Fullerton

Providence Medical Foundation - Virginia K. Crosson Cancer Center - Fullerton, Fullerton, California, United States, 92835

Loma Linda

Local Institution - Unk004, Loma Linda, California, United States, 92354

Los Angeles

Local Institution - 017-961, Los Angeles, California, United States, 90095

San Francisco

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States, 94158

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * All Cohorts: Any prior therapy targeting KRASG12C mutation in any setting
  • * Cohorts A \& E: Prior systemic therapy for locally advanced or metastatic NSCLC, including chemotherapy, immune checkpoint inhibitor therapy or chemoimmunotherapy (note: prior systemic therapy or chemoradiation given in the adjuvant or neoadjuvant setting are allowed if last dose of prior systemic treatment was \>1 year prior to first dose of study treatment)
  • * Cohort C: received maintenance therapy (e.g, pembrolizumab and/or pemetrexed following completion of 4-6 cycles of a platinum-based regimen administered in the first-line setting
  • * Radiation to the lung \> 30 Gy within 6 months prior to first dose of study treatment
  • * Active brain metastases

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mirati Therapeutics Inc.,

Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

2026-12-01